4

Lazertinib

4 Cited Publications

Cat. No.: HY-109061

CAS No.: 1903008-80-9

Purity: 99.87%

Synonyms: YH25448; GNS-1480

Target:

Apoptosis Akt TRP Channel EGFR ERK

Research Areas:

Infection Neurological Disease Metabolic Disease Cancer

Lazertinib (YH25448; GNS-1480) is an orally active, blood-brain barrier permeable third-generation EGFR tyrosine kinase inhibitor, as well as an ABCB1/ABCG2 inhibitor and a TRPA1 activator. Lazertinib exhibits IC₅₀ values of 0.4 mM and 0.2 mM against human ABCB1 and ABCG2, respectively. By inhibiting mutant EGFR signaling, EGFR phosphorylation and the downstream ERK/AKT pathway, as well as upregulating surface expression of EGFR/MET, Lazertinib induces cell cycle arrest, apoptosis, spontaneous calcium responses, hyperexcitability of dorsal root ganglion (DRG) neurons, and TRPA1-dependent pain-like behaviors. Lazertinib competitively binds to the substrate-binding sites of ABCB1/ABCG2, stimulates their ATPase activity without altering their expression or plasma membrane localization, thereby enhancing ADCC activity, acting as a chemosensitizer, and reversing ABCB1-mediated multidrug resistance. It exerts antitumor activity as a single agent or in combination with other drugs. Lazertinib is applicable to research related to non-small cell lung cancer, multidrug-resistant cancers, and paresthesia .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

4

Lazertinib mesylate

4 Cited Publications

Cat. No.: HY-109061B

CAS No.: 2247995-37-3

Synonyms: YH25448 mesylate; GNS-1480 mesylate

Target:

TRP Channel EGFR Akt ERK Apoptosis

Research Areas:

Cancer

Lazertinib (YH25448; GNS-1480) mesylate is an orally active, blood-brain barrier permeable third-generation EGFR tyrosine kinase inhibitor, as well as an ABCB1/ABCG2 inhibitor and a TRPA1 activator. Lazertinib mesylate exhibits IC₅₀ values of 0.4 mM and 0.2 mM against human ABCB1 and ABCG2, respectively. By inhibiting mutant EGFR signaling, EGFR phosphorylation and the downstream ERK/AKT pathway, as well as upregulating surface expression of EGFR/MET, Lazertinib mesylate induces cell cycle arrest, apoptosis, spontaneous calcium responses, hyperexcitability of dorsal root ganglion (DRG) neurons, and TRPA1-dependent pain-like behaviors. Lazertinib mesylate competitively binds to the substrate-binding sites of ABCB1/ABCG2, stimulates their ATPase activity without altering their expression or plasma membrane localization, thereby enhancing ADCC activity, acting as a chemosensitizer, and reversing ABCB1-mediated multidrug resistance. It exerts antitumor activity as a single agent or in combination with other drugs. Lazertinib mesylate is applicable to research related to non-small cell lung cancer, multidrug-resistant cancers, and paresthesia .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

3

Levetiracetam

3 Cited Publications

Cat. No.: HY-B0106

CAS No.: 102767-28-2

Synonyms: UCB L059

Target:

DNA Methyltransferase

Research Areas:

Neurological Disease Cancer

Levetiracetam, an antiepileptic agent, binds the synaptic vesicle protein SV2A. Levetiracetam enhances Temozolomide effect on glioblastoma stem cell proliferation and apoptosis. Levetiracetam modulates HDAC levels ultimately silencing MGMT, thus increasing Temozolomide effectiveness. A chemosensitizer agent .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

Levetiracetam (Standard)

Cat. No.: HY-B0106R

CAS No.: 102767-28-2

Synonyms: UCB L059 (Standard)

Target:

Reference Standards DNA Methyltransferase

Research Areas:

Neurological Disease Cancer

Levetiracetam (Standard) is the analytical standard of Levetiracetam. This product is intended for research and analytical applications. Levetiracetam, an antiepileptic agent, binds the synaptic vesicle protein SV2A. Levetiracetam enhances Temozolomide effect on glioblastoma stem cell proliferation and apoptosis. Levetiracetam modulates HDAC levels ultimately silencing MGMT, thus increasing Temozolomide effectiveness. A chemosensitizer agent .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

Levetiracetam-d6

Cat. No.: HY-B0106S

CAS No.: 1133229-29-4

Synonyms: UCB L059-d₆

Levetiracetam-d₆ is the deuterium labeled Levetiracetam. Levetiracetam, an antiepileptic agent, binds the synaptic vesicle protein SV2A. Levetiracetam enhances Temozolomide effect on glioblastoma stem cell proliferation and apoptosis. Levetiracetam modulates HDAC levels ultimately silencing MGMT, thus increasing Temozolomide effectiveness. A chemosensitizer agent .

Compare

loading...